An Open-Label Pilot Study of Combined Augmentation With Creatine Monohydrate and 5-Hydroxytryptophan for Selective Serotonin Reuptake Inhibitor- or Serotonin-Norepinephrine Reuptake Inhibitor-Resistant Depression in Adult Women
Kious BM, Sabic H, Sung YH, Kondo DG, Renshaw P
Journal of clinical psychopharmacology · 21 citas
Cómo se estudió
- Diseño
- Ensayo clínico controlado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- U.S. Department of Veterans Affairs
- Gobierno
- BLRD VA
- Subvenciones
- U.S. Department of Veterans Affairs (I01 BX002908)
Según 2 financiadores declarados.
Publicación
- Publicado
- 2017-08-05 · J Clin Psychopharmacol · vol. 37 · número 5 · págs. 578–583
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 26 citas · más que el 87% de estudios similares · 2.3× el promedio de su campo
- Referencias
- 52 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Treatment of Major Depression · Neurotransmitter Receptor Influence on Behavior · Digital Mental Health Interventions
- Palabras clave
- Major depressive disorder, Serotonin reuptake inhibitor, Reuptake inhibitor, Serotonin, Placebo, Medicine, Internal medicine, Hamilton Rating Scale for Depression, Depression (economics), Serotonin Uptake Inhibitors, Creatine, Psychology, Anesthesia, Fluoxetine
- MeSH
- humans, creatine, 5-hydroxytryptophan, antidepressive agents, treatment outcome, drug therapy, combination, pilot projects, drug resistance, adult, female, young adult
5 autores
- Brent Michael Kious🇺🇸 · autor de correspondenciaVeterans Health Administration
- Hana Sabic🇺🇸Veterans Health Administration
- Young-Hoon Sung🇺🇸 · autor de correspondenciaVeterans Health Administration
- Douglas G. Kondo🇺🇸 · autor de correspondenciaVeterans Health Administration
- Perry Franklin Renshaw🇺🇸 · autor de correspondenciaVeterans Health Administration
Resumen
El texto original del estudio, en el idioma en que se publicó.
Purpose
Many women with major depressive disorder (MDD) respond inadequately to standard treatments. Augmentation of conventional antidepressants with creatine monohydrate and 5-hydroxytryptophan (5-HTP) could correct deficits in serotonin production and brain bioenergetics associated with depression in women, yielding synergistic benefit. We describe an open-label study of 5-HTP and creatine augmentation in women with MDD who had failed selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) monotherapy.
Methods
Fifteen women who were adequately adherent to an SSRI or SNRI and currently experiencing MDD, with a 17-item Hamilton Depression Rating Scale (HAM-D) score of 16 or higher, were treated with 5 g of creatine monohydrate daily and 100 mg of 5-HTP twice daily for 8 weeks, with 4 weeks of posttreatment follow-up. The primary outcome was change in mean HAM-D scores.
Results
Mean HAM-D scores declined from 18.9 (SD, 2.5) at pretreatment visits to 7.5 (SD, 4.4) (P < 0.00001), a decrease of 60%. Participants did not experience any serious treatment-related adverse events.
Conclusions
Combination treatment with creatine and 5-HTP may represent an effective augmentation strategy for women with SSRI- or SNRI-resistant depression. Given the limitations of this small, open-label trial, future study in randomized, placebo-controlled trials is warranted.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.